European Pharmaceutical Review

NOVEMBER 8, 2022

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.

Biosimilars 52

Biosimilars Pharmaceutical Manufacturing Drug Pricing Pharmaceutical Companies 52

Pharmaceutical Technology

DECEMBER 9, 2022

Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceutical companies of international origin within the country. There are also strict price controls, which in some cases can limit profitability for manufacturers. Brazilian public spending on healthcare, drug pricing reforms and remote medicine.

Drug Pricing 98

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 98

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

Pharma Marketing Network

MAY 11, 2025

accelerates its crackdown on drug pricing through new legislation and regulatory enforcement, pharma companies in China, India, Japan, and South Korea are feeling the ripple effect. This article explores whats behind the sudden slump in Asian pharmaceutical equities and why U.S. As the U.S. Table of Contents The U.S.

Drug Pricing 59

Drug Pricing Biosimilars Communication Pharmaceutical Companies 59

European Pharmaceutical Review

OCTOBER 19, 2022

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment.

Biosimilars 96

Biosimilars Dosage Drug Pricing Pharmaceutical Companies 96

Pharmaceutical Technology

SEPTEMBER 26, 2022

The company told GlobalData PharmSource: “The biosimilar facilities in Austria and Slovenia would continue to manufacture biosimilars for Sandoz under a contractual agreement with Novartis. The company had revenues of $9.6bn both in 2020 and last year. The site employs around 250 people.

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

Pharmaceutical Technology

FEBRUARY 8, 2023

Roche’s market capitalization fell with a decline in sales of their Regeneron-partnered COVID-19 therapy, Ronapreve, and increasing competition from biosimilars for their oncology drugs Avastin, Herceptin, and Rituxan.

Vaccines 78

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 78

Express Pharma

APRIL 1, 2025

Major pharmaceutical companies including Eli Lilly, Pfizer, and Merck are ramping up manufacturing investments in the US to navigate the evolving trade tariffs and capitalise on domestic tax incentives. Lillys CEO has commented that tax cuts passed during President Trumps first term were foundational to these domestic investments.

Biosimilars 66

Biosimilars Drug Pricing Vaccines Pharmaceutical Companies 66

STAT

APRIL 16, 2025

The second seeks to limit providers’ ability to profit from the program by studying and then crafting rules to align prices they pay for drugs with Medicare rates. tariffs on imports, including measures to compensate them for the cost of pharmaceutical innovations , Les Echos reported.

Drug Pricing 146

Drug Pricing Biosimilars Pharmaceutical Companies Pharmaceutical Companies 146

pharmaphorum

JANUARY 22, 2021

We don’t believe there will be draconian price cuts, for the same reason. The Biden administration could put additional scrutiny on drug prices, but more drastic measures, such as allowing Medicare to negotiate with pharma companies directly, are still unlikely.”.

Drug Pricing 63

Drug Pricing Packaging Biosimilars Pharmaceutical Companies 63

STAT

MAY 20, 2025

The Trump administration shared on Tuesday the outlines of how it plans to push pharmaceutical companies to lower their U.S. drug prices to bring them more in line with other nations, kicking off high-stakes negotiations with the companies. Kennedy Jr. said in a statement.

Drug Pricing 286

Drug Pricing Pharmaceutical Manufacturing Biosimilars Pharmaceutical Companies 286

Pharmaceutical Commerce

JUNE 13, 2025

The Trump Administration has revived the most-favored nation (MFN) drug pricing model as a seven-year test, which would tie US drug prices to the lowest prices paid by certain OECD countries—an approach previously blocked by courts. Concerns over price controls. What is MFN model pricing? China wins?

Drug Pricing 52

Drug Pricing Biosimilars Pharmaceutical Companies Pharmaceutical Companies 52